Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The role of Plasmodium in the etiology of acute diarrhea in developing countries remains controversial, and gastrointestinal (GI) symptoms are inconsistently reported in malaria. In this observational case-control study, we investigated the prevalence and risk factors for GI symptoms in hospitalized malarious children aged 1 month to 5 years in northern Uganda. Children with a diagnosis of Plasmodium falciparum malaria were enrolled as cases, and feverish children in whom malaria was excluded were enrolled as controls. Among 451 malarious children, 46.1% had GI symptoms at admission. Compared with controls, the frequency of diarrhea (24.8% versus 11.2%, P < 0.001) and vomiting (35.5% versus 17.5%, P < 0.001) was significantly higher in children with malaria, who had a higher chance of showing either vomiting (odds ratio [OR]: 3.22; 95% CI: 2.14-4.91) or diarrhea (OR: 3.14; 95% CI: 1.99-5.07) at hospital admission. A subgroup analysis performed in children with severe malaria, severe anemia, or high-grade fever confirmed these results. Diarrhea was more frequent in infants and children younger than 3 years than in older children. The analysis of 71 malarious children with diarrhea who received intravenous artesunate showed that the symptom resolved within the first 24 hours since the beginning of the treatment in 85.9% of cases. The 3-fold higher prevalence of diarrhea and vomiting in malarious children compared with febrile controls may provide rationale for incorporating malaria testing in the symptom-guided diagnostic approach of the young child with diarrhea and vomiting in malaria-endemic settings.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866346PMC
http://dx.doi.org/10.4269/ajtmh.20-0287DOI Listing

Publication Analysis

Top Keywords

malarious children
16
children
10
diarrhea
8
plasmodium falciparum
8
falciparum malaria
8
case-control study
8
children malaria
8
diarrhea vomiting
8
malaria
7
diarrhea children
4

Similar Publications

Potential of microRNAs as diagnostic markers for distinguishing malaria severity in samples from an Indian cohort.

BMC Infect Dis

August 2025

Department of Biotechnology, Institute of Applied Sciences & Humanities, GLA University, Mathura, Uttar Pradesh, 281406, India.

Background: Cerebral malaria (CM) is a subcategory of severe malaria (SM) and a major cause of death in Plasmodium falciparum infections, driven by the sequestration of infected red blood cells in the microvasculature of host vital organs. Identifying early biomarkers of CM is crucial for timely intervention. This study assessed the potential of microRNAs, produced upon organ injury, as biomarkers of CM.

View Article and Find Full Text PDF

Background: Anti-malarial artemisinin-based combination therapies (ACTs) might be losing efficacy in east Africa, with the spread of artemisinin partial resistance and reduced partner drug activity. Our trial aimed to measure the efficacies of artemether-lumefantrine, artesunate-amodiaquine, dihydroartemisinin-piperaquine, and artesunate-pyronaridine in three sites in Uganda.

Methods: This randomised, open-label, phase 4 clinical trial was carried out at three sites in the Agago, Arua, and Busia districts of Uganda.

View Article and Find Full Text PDF

Background: Malaria still remains one of the leading causes of death, especially in Africa, with one of the major struggles associated with eradication being resistance to antimalarial medications. Imatinib, a selective tyrosine kinase inhibitor used to treat chronic myeloid leukemia, has emerged as a potential pharmacological approach for malaria management.

Methods: This review synthesizes studies from the inception of the databases of PubMed, Scopus, Google Scholar, Cochrane, Web of Science, and Embase to February 2025, identifying key clinical trials and invitro studies conducted to assess the efficacy and safety of Imatinib in malaria.

View Article and Find Full Text PDF

Hydroxyurea (hydroxycarbamide; HU) has been shown to be a safe and effective drug for individuals living with sickle cell disease (SCD) in Africa. However, reports of large-scale use of HU outside of controlled trial settings are limited on the continent. Access to HU in Ghana has improved through a major public-private partnership aimed at enhancing holistic care for communities affected by SCD.

View Article and Find Full Text PDF

Background: In febrile comatose patients living in malaria-endemic areas, overlapping symptoms and limited laboratory capacity make it difficult to distinguish parasitic, bacterial, and viral central nervous system infections. We evaluated electroencephalography (EEG) as a biomarker to differentiate the microbiologic etiology of pediatric febrile coma at a major referral center in Malawi.

Methods: This was a retrospective case-control study comparing EEG recordings of Malawian children with cerebral malaria to those with febrile coma of nonmalarial cause (bacterial meningitis, viral encephalitis, or unknown cause).

View Article and Find Full Text PDF